SYH2070 clinical trials
How each study uses SYH2070 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SYH2070 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SYH2070
- 1
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 2 |
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test SYH2070.
- Nov 2026A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 InjectionPhase 1 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- Apr 2027A Study of SYH2070 Injection in Participants With Mixed HyperlipidemiaPhase 2 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- Sep 2027Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial HypercholesterolemiaPhase 2 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Studies
Open first, then newest update. How each study uses SYH2070 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial HypercholesterolemiaRecruitingPhase 2CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT07591298Written as SYH2070 injection dose1
- A Study of SYH2070 Injection in Participants With Mixed HyperlipidemiaRecruitingPhase 2CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT07695597Written as SYH2070
- A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 InjectionRecruitingPhase 1CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT07241923Written as SYH2070 injection